Cargando…

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS

Detalles Bibliográficos
Autores principales:	Bittner, Frank, Murchison, Charles, Koop, Dennis, Bourdette, Dennis, Spain, Rebecca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489386/ https://www.ncbi.nlm.nih.gov/pubmed/28680918 http://dx.doi.org/10.1212/NXI.0000000000000380

Ejemplares similares

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial
por: Spain, Rebecca, et al.
Publicado: (2017)

Minocycline-associated vasculitis of extracranial branches of vertebral arteries presenting as myelopathy
por: Garg, Neha, et al.
Publicado: (2014)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial
por: Falardeau, Julie, et al.
Publicado: (2019)

Enlarged perivascular spaces are not associated with vascular co-morbidities, clinical outcomes, and brain volumes in people with secondary progressive multiple sclerosis
por: Wooliscroft, Lindsey, et al.
Publicado: (2020)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Falls in People with Multiple Sclerosis Compared with Falls in Healthy Controls
por: Mazumder, Rajarshi, et al.
Publicado: (2014)

P02.183. Comparing the bioavailability of two forms of lipoic acid in multiple sclerosis
por: Salinthone, S, et al.
Publicado: (2012)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports
por: Körtvélyessy, Peter, et al.
Publicado: (2017)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Longitudinally extensive myelitis in MS mimicking neuromyelitis optica
por: Whittam, Daniel, et al.
Publicado: (2017)

Lipoic Acid Attenuates Inflammation via cAMP and Protein Kinase A Signaling
por: Salinthone, Sonemany, et al.
Publicado: (2010)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Acute liver injury in a Glatopa-treated patient with MS
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

COVID-19 in MS: Initial observations from the Pacific Northwest
por: Bowen, James D., et al.
Publicado: (2020)

Recent developments in multiple sclerosis therapeutics
por: Spain, Rebecca I, et al.
Publicado: (2009)

Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS
por: Vallino, Amélie, et al.
Publicado: (2020)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

pRNFL as a marker of disability worsening in the medium/long term in patients with MS
por: Cordano, Christian, et al.
Publicado: (2018)

IgA autoantibodies against native myelin basic protein in a patient with MS
por: Schumacher, Heike, et al.
Publicado: (2019)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient
por: Massey, Thomas H., et al.
Publicado: (2017)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
por: Maguire, Cole, et al.
Publicado: (2020)

Gray matter blood‐brain barrier water exchange dynamics are reduced in progressive multiple sclerosis
por: Tagge, Ian J, et al.
Publicado: (2021)

Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient: A Case Report
por: Lefeuvre, Lucie, et al.
Publicado: (2022)

Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report
por: Wicklein, Rebecca, et al.
Publicado: (2021)

The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome
por: Graham, Edith, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3sit1nlglq30fu9vrls2uge7hr